

# WHO operational handbook on tuberculosis

Module 3: Diagnosis

Tests for tuberculosis  
infection



World Health  
Organization



# WHO operational handbook on tuberculosis

Module 3: Diagnosis

**Tests for tuberculosis  
infection**

WHO operational handbook on tuberculosis. Module 3: diagnosis. Tests for tuberculosis infection

ISBN 978-92-4-005834-7 (electronic version)

ISBN 978-92-4-005835-4 (print version)

© World Health Organization 2022

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

**Suggested citation.** WHO operational handbook on tuberculosis. Module 3: diagnosis. Tests for tuberculosis infection. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <https://www.who.int/copyright>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Design by Inís Communication

# Contents

|  |           |
|--|-----------|
| <b>Acknowledgements</b>  | <b>v</b>  |
| <b>Abbreviations and acronyms</b>  | <b>vi</b> |
| <b>1. Introduction</b>   | <b>1</b>  |
| 1.1 Rationale for TB infection testing   | 1         |
| 1.2 TB infection tests that are currently recommended by WHO                           | 3         |
| 1.3 The TB infection cascade of care   | 4         |
| 1.4 About this operational handbook  | 4         |
| 1.5 Target audience  | 4         |
| <b>2. Testing for TB infection and a model algorithm</b>                               | <b>5</b>  |
| 2.1 Who should be tested for TB infection?   | 5         |
| 2.2 Risk of disease in those with positive tests for TB infection                      | 6         |
| 2.3 What are the advantages and disadvantages of testing for TB infection?             | 6         |
| 2.4 When is TB infection testing not advised?  | 8         |
| 2.5 An integrated and person-centred model algorithm                                   | 9         |
| <b>3. WHO-recommended tests for TB infection</b>                                       | <b>13</b> |
| 3.1 TB infection skin test using tuberculin (TST)                                      | 13        |
| 3.2 TB infection skin tests using <i>M. tuberculosis</i> -specific antigens            | 15        |
| 3.3 Steps and processes for skin testing   | 19        |
| 3.4 Interferon-gamma release assays  | 24        |
| <b>4. Programmatic considerations for implementing TB infection tests</b>              | <b>29</b> |
| 4.1 General considerations: integrated and person-centred TB infection cascade of care | 29        |
| 4.2 Steps for programmatic implementation of testing for TB infection                  | 32        |
| <b>References</b>  | <b>49</b> |

|   |           |
|---|-----------|
| <b>Annex 1. Skin tests for tuberculosis infection – detailed description.....</b> | <b>55</b> |
| <b>Annex 2. Interferon-gamma release assays – detailed description.....</b>       | <b>63</b> |

**Web Annex. Use of alternative interferon-gamma  
release assays for the diagnosis of TB infection**

# Acknowledgements

This operational handbook was led by Nazir Ahmed Ismail, Carl-Michael Nathanson, Dennis Falzon, Alexei Korobitsyn and Avinash Kanchar, with support from Cecily Miller and Matteo Zignol, under the overall direction of Tereza Kasaeva, Director of the World Health Organization (WHO) Global TB Programme (GTB). The first draft was written by Richard (Dick) Menzies, Lika Apriani and Anete Trajman from the McGill International TB Centre, Canada. WHO/GTB gratefully acknowledges the support of the following experts who have contributed to the review of the document: Christopher Coulter, Queensland Mycobacterium Reference Laboratory, Australia; Rumina Hasan, Department of Pathology and Microbiology, Aga Khan University, Karachi, Pakistan; Afrânio Lineu Kritski, University of Rio de Janeiro, Brazil; Siva Kumar Shanmugam, Department of Bacteriology, National Institute for Research in Tuberculosis, Indian Council of Medical Research, India; Irina Lyadova, Laboratory of Cellular and Molecular Basis of Histogenesis, Koltzov Institute of Developmental Biology of the Russian Academy of Sciences, Russian Federation; Alberto Matteelli, University of Brescia, Italy; Jeremiah Chakaya Muhwa, Co-chair, International Union Against Tuberculosis and Lung Disease, Nairobi, Kenya; Shaheed Vally Omar, Centre for Tuberculosis, National Institute for Communicable Diseases/National Health Laboratory Service and WHO SRL, Johannesburg, South Africa; and Thomas Shinnick, independent consultant, United States of America.

This product was developed with support from the United States Agency for International Development (USAID).

# Abbreviations and acronyms

|                |  |
|----------------|--|
| <b>AIDS</b>    | acquired immunodeficiency syndrome                         |
| <b>BCG</b>     | bacille Calmette-Guérin (vaccine)                          |
| <b>CFP-10</b>  | culture filtrate protein 10                                |
| <b>CXR</b>     | chest radiography (X-ray)                                  |
| <b>ELISA</b>   | enzyme-linked immunosorbent assay                          |
| <b>ELISPOT</b> | enzyme-linked immunosorbent spot                           |
| <b>ESAT-6</b>  | early secretory antigenic 6 kDa                            |
| <b>HIV</b>     | human immunodeficiency virus                               |
| <b>IGRA</b>    | interferon-gamma release assay                             |
| <b>IT</b>      | information technology                                     |
| <b>LMIC</b>    | low- and middle-income countries                           |
| <b>mRNA</b>    | messenger ribonucleic acid                                 |
| <b>NTP</b>     | national TB programme                                      |
| <b>PBMC</b>    | peripheral blood mononuclear cell                          |
| <b>PLHIV</b>   | people living with HIV                                     |
| <b>PPD</b>     | purified protein derivative                                |
| <b>PPDS</b>    | standard PPD   |
| <b>QA</b>      | quality assurance  |
| <b>QC</b>      | quality control  |
| <b>QFT</b>     | QIAGEN QuantiFERON®-TB                                     |
| <b>SOP</b>     | standard operating procedure                               |
| <b>TB</b>      | tuberculosis   |
| <b>TBST</b>    | <i>Mycobacterium tuberculosis</i> antigen-based skin tests |
| <b>TNF</b>     | tumour necrosis factor                                     |

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_31944](https://www.yunbaogao.cn/report/index/report?reportId=5_31944)

